WT1 and myelodysplastic syndrome: In a therapy-related MDS patient who had relapsed after allo-HSCT, treatment with azacitidine combined with DLI yielded a strong GvL effect along with WT1-specific CD8+ T cell responses that resulted in remission for 15 months before the patient finally relapsed (149).